港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

维立志博-B

62.200

+0.1000.16%

成交量：54.81万

成交额：3,400.91万

市值：123.78亿

市盈率：-30.98

高：65.100

开：62.300

低：60.400

收：62.100

52周最高：83.600

52周最低：44.720

股本：1.99亿

香港流通股本：1.53亿

量比：0.30

换手率：0.36%

股息：- -

股息率：- -

每股收益(LYR):-2.008

净资产收益率：--

总资产收益率：--

市净率：104.13

市盈率(LYR):-30.98

市销率: - -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

维立志博-B盘中涨超8% 正式进入港股通股票名单

维立志博-B获纳入恒生综合指数成份股及获调入港股通股票名单

维立志博-B(09887)获纳入恒生综合指数成份股及获调入港股通股票名单

维立志博-B(09887)：维利信™于一线食管鳞状细胞癌II期试验的首例患者入组

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/09887"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":62.2,"timestamp":1773389300007,"preClose":62.1,"halted":0,"volume":548102,"delay":0,"changeRate":0.0016103059581320679,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"休市中","change":0.1,"latestTime":"03-13 16:08:20","open":62.3,"high":65.1,"low":60.4,"amount":34009078,"amplitude":0.075684,"askPrice":62.3,"askSize":300,"bidPrice":62.2,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773624600000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":62.1,"openAndCloseTimeList":[[1773365400000,1773374400000],[1773378000000,1773388800000]],"volumeRatio":0.295797,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":0.295797,"shares":199000000,"dividePrice":0,"high":65.1,"amplitude":0.075684,"preClose":62.1,"low":60.4,"week52Low":44.72,"pbRate":"104.13","week52High":83.6,"institutionHeld":0,"latestPrice":62.2,"committee":-0.2,"eps":-2.008042,"divideRate":0,"volume":548102,"delay":0,"ttmEps":-1.583,"open":62.3,"prevYearClose":51,"prevWeekClose":53.85,"prevMonthClose":62.7,"prevQuarterClose":51,"fiveDayClose":53.85,"twentyDayClose":63.65,"sixtyDayClose":53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-03-12","current":-39.292483,"percent":0.529032,"low":-50.052922,"twenty":-41.93996,"median":-37.973315,"eighty":-33.407237,"high":-30.202688,"avg":-38.122521,"sd":4.460799,"marketCap":12351180780},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-12","current":-37.739566,"twenty":-41.93996,"median":-37.973315,"eighty":-33.407237,"marketCap":12351180780}],"updateTime":1773400883915},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618761585","title":"维立志博-B盘中涨超8% 正式进入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2618761585","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618761585?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 10:35","pubTimestamp":1773023700,"startTime":"0","endTime":"0","summary":"　　维立志博-B盘初涨超8%，截至发稿，股价上涨6.04%，现报57.10港元，成交额1.15亿港元。　　维立志博公布，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。　　此外，3月6日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究顺利完成首例患者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-09/doc-inhqizzu7097010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","VT","VXUS","HK0000252152.HKD","BK4585","09887","BK4588"],"gpt_icon":0},{"id":"2617666837","title":"维立志博-B获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617666837","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617666837?lang=zh_cn&edition=fundamental","pubTime":"2026-03-08 10:08","pubTimestamp":1772935680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　维立志博-B（09887）发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。\n　　股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-08/doc-inhqfsuq1032680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VT","09887","VXUS","HK0000500386.USD","BK1161","HK0000252160.HKD","BK4588","BK4585","HSCI","HK0000252152.HKD"],"gpt_icon":0},{"id":"2617857206","title":"维立志博-B(09887)获纳入恒生综合指数成份股及获调入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617857206","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617857206?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 17:15","pubTimestamp":1772788549,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，自2026年3月9日起，公司股份将获恒生指数有限公司纳入恒生综合指数成份股及获调入港股通标的名单。股份获纳入恒生综合指数及港股通标的证券是资本市场对公司表现及价值的高度认可，并允许中国内地合资格投资者透过沪港通及深港通机制直接投资于香港联合交易所有限公司上市的股份。预期纳入将进一步扩大公司的投资者基础，提升股份的交易流动性，并进一步优化股东结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","BK4585","VT","BK4588","VXUS","HK0000252152.HKD","HSCI","BK1161","HK0000252160.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"2617683670","title":"维立志博-B(09887)：维利信™于一线食管鳞状细胞癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617683670?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 16:33","pubTimestamp":1772786017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信™(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线食管鳞状细胞癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳院长牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线食管鳞状细胞癌患者的有效性和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0}],"pageSize":4,"totalPage":41,"pageCount":1,"totalSize":162,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09887\",params:#limit:6,delay:false,,,undefined,":[]}}